Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Graymark Healthcare acquires four pharmacies in Greater Chicago
The acquisition brings the total number of pharmacies acquired by the Graymark Healthcare subsidiary to 18 in the 23 months of operations since it was founded in July
The acquisition brings the total number of pharmacies acquired by the Graymark Healthcare subsidiary to 18 in the 23 months of operations since it was founded in July
The primary endpoint of the Bio-Seal study is a reduction in the incidence of pneumothorax in patients undergoing lung biopsy procedures when compared with patients who do not
The company further announced that the investigational new drug (IND) is now effective and that it may commence clinical studies under this IND. With the new investigational new
To support this approval, Bradmer previously submitted the Chemistry, Manufacturing and Control (CMC) dossier, as well as the clinical protocol and related trial design and execution documents to
With the investigational new drug (IND) acceptance, the company will involve US clinical centers in the development of MitoQ for the treatment of liver diseases such as non-alcoholic
Under the terms of the Settlement Agreement, AngioDynamics has agreed to pay Vnus Medical approximately $6.8 million and a royalty, payable quarterly, on US sales of NeverTouch VenaCure
The new dosing regimen of Pennsaid will be 50 drops per knee, three times a day, as an alternative to the existing approved dosing regimen of 40 drops
The planned study is a multicenter, randomized, double-blind, placebo- controlled, two-stage exploratory study to evaluate the safety, tolerability, efficacy and pharmacokinetics of a single dose of Adlea compared
Seventy-eight patients with previously untreated diffuse large B-cell lymphoma were eligible to participate in this Phase II open-label study led by Mayo Clinic, Rochester, Minnesota. The primary endpoint
The Phase II study was designed to evaluate the safety and efficacy of Intestinal Trefoil Factor (rhITF) as an oral spray to prevent oral mucositis. rhITF treatment was